LOGIN  |  REGISTER
Assertio
Recursion

CVS Health to hold first quarter 2024 earnings conference call

April 01, 2024 | Last Trade: US$66.88 1.67 -2.44

WOONSOCKET, R.I., April 1, 2024 /PRNewswire/ -- CVS Health (NYSE: CVS) will hold a conference call with analysts and investors on Wednesday, May 1st, 2024, at 8:00 a.m. ET to discuss first quarter 2024 financial results.

An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year.

About CVS Health

CVS Health® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues — including more than 40,000 physicians, pharmacists, nurses and nurse practitioners. Wherever and whenever people need us, we help them with their health — whether that's managing chronic diseases, staying compliant with their medications or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system — and their personal health care — by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.

 

Chimerix

Stock Quote

Last Trade: US$66.88
Daily Change: -1.67 -2.44
Daily Volume: 15,611,840
Market Cap: US$84.270B

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page